600993.SH
马应龙
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 22.73
−1.22%Year over year
Reported trailing growth
- Revenue
- +4.5%
- EBITDA
- —
- EBIT
- +8.3%
- EPS
- +10.7%
- Free cash flow
- +51.3%
- Operating cash flow
- +15.9%
Forward estimates
Based on analyst estimates
- Revenue
- -74.2%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +3.1%
- EBITDA
- +8.9%
- EBIT
- +9.0%
- Net income
- +6.7%
- EPS
- +6.7%
- Free cash flow
- +21.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026